# Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Source: https://onco.cc/trials/nct05969041/  
OnCo record `nct05969041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is recruiting.

## Summary

The registry lists NCT05969041 as recruiting, last updated 2024-01-18. Enrolment is 48 planned participants, an estimate. Interventions: MT-302 (A). Primary measures include To evaluate the safety and tolerability of MT-302 through incidence of Adverse Events; To establish the maximum tolerated dose (MTD). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT05969041
- Phase: 1
- Setting: MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
- Sponsor: Myeloid Therapeutics

## Sources

- ClinicalTrials.gov NCT05969041: https://clinicaltrials.gov/study/NCT05969041

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [MT-302](https://onco.cc/drugs/mt-302/)

---
JSON: https://onco.cc/api/v1/entities/nct05969041.json